KALA BIO, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that KALA BIO, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.56M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($11.16M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($8.95M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($8.95M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($9.58M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($11.81M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($8.70M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.41M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.46M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | $29.07M | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($28.11M) | Aug 4, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($32.94M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($28.13M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($36.50M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($30.41M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($27.95M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($23.31M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($21.96M) | May 5, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($23.18M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($23.83M) | Aug 6, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.24M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($11.03M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.67M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($9.99M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($9.61M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($11.93M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($8.76M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($9.60M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.68M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.57M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($25.97M) | Aug 4, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($30.91M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($26.07M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($29.05M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($28.31M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($25.84M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($21.28M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($20.13M) | May 5, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($21.57M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($22.41M) | Aug 6, 2020 |